Drug Delivery

Hey students! 👋 Welcome to one of the most exciting areas of modern pharmacy - drug delivery systems! This lesson will take you on a journey through the fascinating world of how we get medications to exactly where they need to go in your body. You'll discover how scientists have revolutionized medicine by creating smart delivery systems that can target specific cells, release drugs at just the right time, and even use tiny robots smaller than a strand of hair! By the end of this lesson, you'll understand controlled release systems, targeted delivery methods, nanocarriers, and biologic delivery strategies that are transforming healthcare today.

Understanding Drug Delivery Systems

Traditional drug delivery is like throwing a handful of seeds randomly across a field and hoping some land in the right spot 🌱. Modern drug delivery systems, however, are like precision farming - we know exactly where to plant each seed and when to water it for maximum growth!

A drug delivery system is essentially a method or device that transports a pharmaceutical compound to its target site in the body. Think of it as a sophisticated postal service for medications. The global drug delivery market was valued at approximately $1.8 trillion in 2023 and is expected to reach $2.3 trillion by 2028, showing just how rapidly this field is growing.

The human body presents unique challenges for drug delivery. When you swallow a pill, it must survive the acidic environment of your stomach (pH around 1.5-2), navigate through your intestines, enter your bloodstream, and somehow find its way to the specific organ or tissue that needs treatment. Along this journey, your liver might break down the drug, your kidneys might filter it out, and healthy tissues might be affected by the medication meant for diseased cells.

Traditional oral medications have a bioavailability (the percentage of drug that reaches systemic circulation) ranging from 10-90% depending on the drug. This means that sometimes only 10% of the medicine you take actually reaches where it needs to go! Modern delivery systems aim to dramatically improve these numbers while reducing side effects.

Controlled Release Systems

Imagine if your smartphone battery could release energy slowly and steadily for exactly 24 hours instead of draining quickly 🔋. That's essentially what controlled release drug systems do - they provide a steady, predictable release of medication over time.

Controlled release systems work through several mechanisms. Matrix tablets embed drugs in a polymer matrix that slowly dissolves or erodes, releasing the drug at a controlled rate. Reservoir systems surround the drug core with a rate-controlling membrane, like a tiny time-release capsule. Osmotic systems use osmotic pressure to push drug solution through a small hole in the tablet coating.

One excellent real-world example is the nicotine patch used for smoking cessation. Instead of the rapid nicotine spikes and crashes from cigarettes, the patch delivers a steady amount of nicotine through the skin over 24 hours. This maintains blood nicotine levels between 10-20 ng/mL, compared to the 30-50 ng/mL spikes from cigarettes followed by rapid drops.

Extended-release medications like Concerta (methylphenidate) for ADHD use an osmotic system called OROS. The tablet has three layers: an immediate-release outer layer, an osmotic layer, and a drug layer. Water enters the tablet, swells the osmotic layer, and pushes drug solution through a laser-drilled hole. This provides 12 hours of consistent medication levels, allowing students to focus throughout their entire school day with just one morning dose.

The mathematical relationship for zero-order release (constant rate) follows: $Q = Q_0 + K_0t$ where Q is the amount released at time t, $Q_0$ is the initial amount, and $K_0$ is the release rate constant.

Targeted Drug Delivery

Targeted delivery is like having a GPS system for your medications 🎯. Instead of affecting your entire body, these systems deliver drugs specifically to diseased tissues while sparing healthy ones.

Passive targeting takes advantage of natural biological processes. Cancer tumors, for example, have leaky blood vessels and poor lymphatic drainage - a phenomenon called the Enhanced Permeability and Retention (EPR) effect. Nanoparticles between 10-200 nanometers can squeeze through these leaky vessels and accumulate in tumors. This is why many cancer nanomedicines are designed within this size range.

Active targeting uses specific molecular recognition. Antibodies, peptides, or other ligands are attached to drug carriers to bind to receptors overexpressed on target cells. For instance, Herceptin (trastuzumab) specifically targets HER2 receptors that are overexpressed in about 20% of breast cancers. This targeted approach improves treatment effectiveness while reducing damage to healthy breast tissue.

Physical targeting uses external forces to direct drugs to specific locations. Magnetic drug targeting uses magnetic nanoparticles that can be guided by external magnetic fields. Researchers have achieved drug concentrations 10-100 times higher at target sites compared to non-targeted delivery using this approach.

Liposomal doxorubicin (Doxil) is a FDA-approved example that demonstrates the power of targeting. Regular doxorubicin causes severe heart toxicity, but when encapsulated in liposomes, it preferentially accumulates in tumors through the EPR effect. This reduces cardiac side effects by 3-5 fold while maintaining anti-cancer effectiveness.

Nanocarriers: The Tiny Delivery Trucks

Nanocarriers are incredibly small delivery vehicles - so tiny that about 80,000 of them could fit across the width of a human hair! 🔬 These microscopic carriers include liposomes, polymeric nanoparticles, dendrimers, carbon nanotubes, and micelles.

Liposomes are spherical vesicles made of phospholipids - the same material as cell membranes. They can carry both water-loving (hydrophilic) drugs in their aqueous core and fat-loving (lipophilic) drugs in their lipid bilayer. The first FDA-approved liposomal drug was Doxil in 1995, and today the liposomal drug delivery market is worth over $4 billion annually.

Polymeric nanoparticles are made from biodegradable polymers like PLGA (poly lactic-co-glycolic acid). These particles can be engineered to release drugs over days, weeks, or even months. Risperdal Consta, a monthly injection for schizophrenia, uses PLGA microspheres to provide sustained drug release, improving patient compliance from daily oral dosing to monthly injections.

Dendrimers are tree-like branched molecules with precise molecular weights and structures. Each generation of branching doubles the number of surface groups available for drug attachment. G4 PAMAM dendrimers, for example, have 64 surface amino groups that can carry multiple drug molecules or targeting ligands.

The size of nanocarriers dramatically affects their behavior. Particles smaller than 10 nm are rapidly cleared by the kidneys, while those larger than 200 nm are quickly captured by the liver and spleen. The "sweet spot" of 10-200 nm allows nanocarriers to circulate in the bloodstream long enough to reach their targets.

Surface charge also matters tremendously. Positively charged nanoparticles interact strongly with negatively charged cell membranes but are quickly cleared by the immune system. Neutral or slightly negative particles circulate longer. PEGylation (coating with polyethylene glycol) creates a "stealth" effect, allowing nanocarriers to avoid immune detection and circulate for hours or days instead of minutes.

Biologic Delivery Strategies

Biologics are large, complex molecules like proteins, antibodies, and gene therapies that represent the cutting edge of modern medicine 💊. However, delivering these delicate molecules presents unique challenges because they're easily destroyed by stomach acid, enzymes, and immune responses.

Protein and peptide delivery requires special protection strategies. Insulin, a 51-amino acid protein, must be injected because oral delivery would result in complete destruction by digestive enzymes. However, researchers have developed innovative approaches like inhaled insulin (Afrezza) that delivers insulin through the lungs, providing rapid absorption similar to injection.

Monoclonal antibody delivery typically requires intravenous infusion because these large molecules (150,000 Da molecular weight) cannot cross biological barriers easily. Subcutaneous formulations use hyaluronidase enzymes to temporarily increase tissue permeability, allowing antibodies to be absorbed into systemic circulation. This has transformed cancer treatment - patients can now receive antibody therapy at home instead of spending hours in infusion centers.

Gene therapy delivery faces the challenge of getting genetic material into specific cells and then into the cell nucleus. Viral vectors like adeno-associated virus (AAV) are naturally equipped to enter cells and have been engineered to be safe. Luxturna, an FDA-approved gene therapy for inherited blindness, uses AAV to deliver functional genes directly to retinal cells through a single injection into the eye.

mRNA delivery, revolutionized by COVID-19 vaccines, uses lipid nanoparticles to protect fragile mRNA molecules and deliver them into cells. The Pfizer-BioNTech vaccine uses four different lipids to create nanoparticles about 100 nm in diameter. These particles fuse with cell membranes, releasing mRNA that instructs cells to produce the spike protein, triggering immune protection.

Cell and tissue engineering approaches use living cells as delivery vehicles. CAR-T cell therapy genetically modifies a patient's T-cells to recognize and attack cancer cells. These "living drugs" can multiply in the body and provide long-lasting therapeutic effects. Kymriah, approved for certain blood cancers, has achieved remission rates of 70-90% in patients who had failed other treatments.

Conclusion

Drug delivery systems have transformed from simple pills and injections into sophisticated, intelligent therapeutic platforms. Controlled release systems provide steady medication levels, targeted delivery minimizes side effects while maximizing efficacy, nanocarriers act as protective vehicles for delicate drugs, and biologic delivery strategies enable the use of complex therapeutic molecules. These advances are not just laboratory curiosities - they're improving millions of lives by making treatments more effective, convenient, and safer. As you continue your pharmacy studies, remember that the future of medicine lies not just in discovering new drugs, but in developing smarter ways to deliver them exactly where and when they're needed.

Study Notes

• Drug delivery system: Method or device that transports pharmaceutical compounds to target sites in the body

• Bioavailability: Percentage of administered drug that reaches systemic circulation (ranges 10-90% for oral drugs)

• Controlled release mechanisms: Matrix tablets, reservoir systems, osmotic systems (OROS)

• Zero-order release equation: $$Q = Q_0 + K_0t$$

• EPR effect: Enhanced Permeability and Retention - allows nanoparticles to accumulate in tumors

• Optimal nanocarrier size: 10-200 nm for effective circulation and targeting

• Passive targeting: Uses natural biological processes (EPR effect)

• Active targeting: Uses molecular recognition (antibodies, ligands)

• Physical targeting: Uses external forces (magnetic fields)

• Liposomes: Phospholipid vesicles that can carry both hydrophilic and lipophilic drugs

• PLGA: Biodegradable polymer used for sustained release (days to months)

• PEGylation: Coating nanocarriers with polyethylene glycol for "stealth" properties

• Biologics: Large, complex therapeutic molecules (proteins, antibodies, genes)

• Viral vectors: Modified viruses used for gene delivery (AAV commonly used)

• mRNA delivery: Uses lipid nanoparticles (~100 nm) to protect and deliver genetic material

• CAR-T therapy: Genetically modified patient T-cells that act as "living drugs"